Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 161Lymphoid 82Genitourinary 29Myeloid 21Breast 7Sarcoma 6Classical hematology 6Gynecologic 4Tumor-Agnostic 2Plasma cell 2Thoracic 1Other solid neoplasm 1Head & Neck 1Endocrine 1

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1

Interventions

Dexamethasone 881Bortezomib 479Lenalidomide 467Cyclophosphamide 367Melphalan 275Calcium Dobesilate 265daratumumab 240pomalidomide 215carfilzomib 188fludarabine phosphate 141fludarabine 137Thalidomide 125Peripheral Blood Stem Cell Transplantation 120Filgrastim 115ixazomib 94Mycophenolic Acid 91Granulocyte Colony-Stimulating Factor 90Busulfan 89Whole-Body Irradiation 88dexamethasone acetate 87Tacrolimus 79dexamethasone 21-phosphate 74isatuximab 69Cyclosporine 68auricularum 67Prednisone 67elotuzumab 63belantamab mafodotin 60Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Mitoxantrone × Plasma cell × Clear all
NCT00005987 2017-11-29

Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
87 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00100477 2013-09-25

Use of Topotecan in Patients With Refractory Acute Leukemia

VA Office of Research and Development

Phase 2 Completed
10 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡